NM_000527.5:c.2389+8C>T
Variant summary
Our verdict is Uncertain significance. Variant got -1 ACMG points: 0P and 1B. BP4
This summary comes from the ClinGen Evidence Repository: The NM_000527.4(LDLR):c.2389+8C>T variant is classified as variant of Uncertain significance for Familial Hypercholesterolemia by evaluating evidence codes (BP4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755).The supporting evidence is as follows: BP4 - no REVEL, splicing evaluation required. No functional assay on splicing. not on splicing limits, so BP4 is met. LINK:https://erepo.genome.network/evrepo/ui/classification/CA040318/MONDO:0007750/013
Frequency
Consequence
NM_000527.5 splice_region, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got -1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LDLR | NM_000527.5 | c.2389+8C>T | splice_region_variant, intron_variant | Intron 16 of 17 | ENST00000558518.6 | NP_000518.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000118 AC: 18AN: 152122Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.000163 AC: 41AN: 251312Hom.: 0 AF XY: 0.000125 AC XY: 17AN XY: 135870
GnomAD4 exome AF: 0.0000458 AC: 67AN: 1461382Hom.: 0 Cov.: 32 AF XY: 0.0000495 AC XY: 36AN XY: 727018
GnomAD4 genome AF: 0.000118 AC: 18AN: 152240Hom.: 0 Cov.: 31 AF XY: 0.000121 AC XY: 9AN XY: 74422
ClinVar
Submissions by phenotype
Familial hypercholesterolemia Benign:2
- -
- -
Hypercholesterolemia, familial, 1 Uncertain:1
The NM_000527.4(LDLR):c.2389+8C>T variant is classified as variant of Uncertain significance for Familial Hypercholesterolemia by evaluating evidence codes (BP4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: BP4 - no REVEL, splicing evaluation required. No functional assay on splicing. not on splicing limits, so BP4 is met. -
Cardiovascular phenotype Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at